C ombined antithrombotic and antiplatelet drugs are the mainstay therapy of patients with acute coronary syndromes and of those undergoing percutaneous coronary intervention (PCI) both in the acute phase and in terms of chronic maintenance therapy. Intensified therapy, through the use of either combined drug regimens or new potent agents, has reduced the incidence of ischemic complications but has increased the bleeding risk in patients with acute coronary syndromes and in those treated with PCI procedures. Ample evidence demonstrates that patients with acute coronary syndromes and those undergoing PCI who bleed have worse clinical outcomes than those patients who do not bleed. [1] [2] [3] [4] [5] [6] [7] Increased awareness about the deleterious effects of bleeding after PCI procedures has prompted adaptation of various strategies that seek to reduce their incidence. 8, 9 However, a variable definition of bleeding has represented an important confounding factor hindering the ascertainment of true bleeding occurrence and, as a consequence, its association with clinical outcome and implementation of preventive/reducing strategies. 10, 11 
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Recently, a consensus report from the Bleeding Academic Research Consortium (BARC) proposed standardized bleeding definitions through the use of a hierarchical approach of describing bleeding severity grade in patients receiving antithrombotic therapy. 12 Although several questions regarding the applicability of the proposed bleeding definitions still remain to be addressed, 13 clinical trials have already started to include BARC definitions in their endpoint assessment protocols. 14 However, the BARC document is a consensus report, rather than a data-based analysis. In order for the BARC unified definition of bleeding to be widely accepted in clinical trials and real-world clinical practice, it must be validated with the use of either existing data sets or data collected by specifically designed future clinical trials.
The aim of the present study was to validate the BARC bleeding definitions. Specifically, the objective of the present study was 2-fold: (1) to investigate the relationship between bleeding complications as defined by the BARC consensus document and 1-year mortality in patients undergoing PCI; and (2) to assess whether the BARC bleeding definition is superior to existing bleeding definitions in regard to mortality prediction in patients undergoing PCI procedures.
Methods Patients
This study represents a pooled patient-level analysis of 12 459 patients recruited in 6 Intracoronary Stenting and Antithrombotic Regimen (ISAR) clinical trials: the ISAR-REACT (Intracoronary Stenting and Antithrombotic Regimen-Rapid Early Action for Coronary Treatment), 15 ISAR-SWEET (Intracoronary Stenting and Antithrombotic Regimen: Is Abciximab a Superior Way to Eliminate Elevated Thrombotic Risk in Diabetics), 16 ISAR-SMART (Intracoronary Stenting to Abrogate Restenosis in Small Arteries)-2, 17 ISAR-REACT-2, 18 ISAR-REACT-3, 19 and ISAR-REACT-3A. 20 Patients in the 6 trials were recruited between June 2000 and February 2010. The first 4 trials were randomized, placebo-controlled trials addressing whether an added benefit existed from the glycoprotein IIb/IIIa inhibitor abciximab in patients with various forms of presentation of coronary artery disease undergoing PCI after a 600-mg loading dose of clopidogrel. [15] [16] [17] [18] The ISAR-REACT-3 trial was a randomized, double-blind trial comparing bivalirudin with unfractionated heparin in patients with stable or unstable angina undergoing PCI after a 600-mg loading dose of clopidogrel. 19 The ISAR-REACT-3A trial was a prospective, multicenter, single-arm, open-label trial in which the 100-U unfractionated heparin arm was compared with the 140-U unfractionated heparin arm of the ISAR-REACT-3 trial (historical control). 20 All patients received 325 to 500 mg of aspirin.
In all 6 trials, written informed consent was required for participation, and an institutional review board approved each study at all participating centers.
Study Protocols (Antithrombotic Drugs)
Detailed study protocols and inclusion/exclusion criteria are shown in the primary publications [15] [16] [17] [18] [19] [20] and in the online-only Data Supplement. Patients were randomized after the decision to perform a PCI was made but before the guidewire had crossed the lesion, with sealed opaque envelopes containing the block randomization sequence for each participating center. In the first 4 trials, patients in the abciximab group received a bolus of abciximab 0.25 mg/kg body wt followed by an infusion of 0.125 g/kg per minute (a maximum of 10 g/min) for 12 hours and a 70-U/kg bolus of heparin intravenously. Patients in the placebo group received a bolus and a 12-hour continuous infusion of placebo, as well as a 140-U/kg bolus of intravenous heparin. In the ISAR-REACT-3 trial, patients assigned to bivalirudin received a bolus of 0.75 mg of bivalirudin per kilogram, followed by an infusion of 1.75 mg/kg per hour for the duration of the procedure, whereas patients assigned to heparin received a bolus of 140 U of heparin per kilogram, followed by a placebo infusion for the duration of the procedure. In each trial, double blinding was achieved by using identical vials for the study drugs. No patients required unblinding, and there were no crossovers. The 100-U arm of the ISAR-RACT3A trial received 1 open-label bolus of 100 U/kg body wt unfractionated heparin.
Coronary stenting with either bare-metal or drug-eluting stents was performed according to standard practice. Sheaths were removed, and manual compression was applied as soon as the activated partial thromboplastin time fell below 50 seconds. Vascular-access closure devices were used in Ͻ10% of the patients. Postprocedural therapy included aspirin (80 -325 mg/d indefinitely), clopidogrel (75-150 mg/d until discharge but for no longer than 3 days, followed by 75 mg/d for at least 1 month, in patients with bare-metal stents or 6 months in patients with drug-eluting stents). Other cardiac medications were prescribed at the discretion of the patient's physician.
The local research coordinators collected the data and forwarded them to the data coordinating center. The quality of data collection was assessed by checking source documentation in random samples. Angiographic data were analyzed by the same quantitative angiographic core laboratory.
Endpoint Definition and Follow-Up
The primary outcome of this study was 1-year mortality. In the present analysis, in-hospital bleeding events were assessed with the use of 3 different criteria: Thrombolysis in Myocardial Infarction (TIMI), 21 Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE-2), 22 and BARC 12 criteria. Bleeding definitions according to all 3 criteria are provided in Table  I in the online-only Data Supplement. TIMI major and minor bleeding, REPLACE-2 major bleeding, and classes 1 to 4 of the BARC-defined bleeding were analyzed. Reporting of every case of bleeding was required in all trials included in this pooled analysis. For every case with bleeding, source documentation was available, and it was reevaluated. We had information on localization, imaging tests, hemoglobin level, hematocrit, and blood transfusion. For patients who underwent coronary artery bypass graft surgery during the index hospitalization, patients' charts were reexamined for the occurrence of bleeding and its characteristics. Because the primary outcome of this analysis was mortality, bleeding events potentially belonging to class 5 of the BARC-defined bleeding (fatal bleeding) were not analyzed as a separate class but were distributed to other classes according to initial assessment. TIMI bleeding criteria were prospectively evaluated in all included trials; REPLACE-2 bleeding criteria were retrospectively assessed in the first 4 trials and prospectively in ISAR-REACT-3 trials; and BARC bleeding definition criteria were retrospectively analyzed in all included trials. Adjudication of the BARC bleeding events was performed by personnel unaware of bleeding events assessed by the other 2 criteria and not involved in the primary studies.
All patients were either seen by their physician or interviewed by telephone at 30 days, 6 months, and 1 year after the procedure; patients with cardiac complaints underwent a complete clinical, ECG, and laboratory evaluation. Information on deaths was obtained from hospital records, death certificates, or telephone contact with relatives of the patient or referring physician. The local research coordinators collected the data and forwarded them to the data coordinating center. The quality of data collection was assessed by checking source documentation in random samples. Angiographic data were analyzed by the same quantitative angiographic core laboratory.
Statistical Analysis
The data are presented as median (25th, 75th percentiles) or as counts (percentages). The normality of distribution was assessed with the 1-sample Kolmogorov-Smirnov test. Landmark analysis with a prespecified landmark at 1 month was performed to assess early and late relative risk of death associated with bleeding. Sensitivity, specificity, and accuracy with respect to 1-year mortality were calculated for BARC, TIMI, and REPLACE-2 criteria with the use of standard formulas and compared with the McNemar test. A univariable and multivariable Cox proportional hazards model was used to assess independent correlates of 1-year mortality. All variables of Table 1 plus study type and study treatment and occurrence of bleeding defined as BARC class Ն2, BARC class Ն3, TIMI (major plus minor bleeding), or REPLACE-2 (major bleeding) were entered into the models for 1-year mortality. The proportional hazards assumption was checked by the method of Grambsch and Therneau 23 and was fulfilled in all cases in which we used Cox proportional hazards models. One-year survival was estimated by applying the Kaplan-Meier method and by calculating the hazard ratios with 95% confidence intervals associated with 1-year mortality. The discriminatory power of multivariable models without and with bleeding events according to BARC, TIMI, or REPLACE-2 definition criteria was assessed by performing receiver operating characteristic curve analysis and by calculating the integrated discrimination improvement (IDI) according to Pencina et al. 24 Multivariable models were used to construct adjusted receiver operating characteristic curves and to compute areas under the curve (AUC). The same variables as for the Cox proportional hazards model with adjustment for the association between bleeding and mortality were entered into the models of adjusted receiver operating characteristic curves. Bootstrapping (400 samples) was used to calculate confidence intervals of AUC and to enable comparison of the IDI of the models with bleeding events according to BARC, TIMI, or REPLACE-2 criteria. All analyses were performed with the use of the S-plus statistical package (S-PLUS, Insightful Corp, Seattle, WA). A 2-sided P value Ͻ0.05 was considered to indicate statistical significance.
Results
Overall, this study included 12 459 patients recruited in 6 ISAR trials. In 11 400 patients (91.5%), coronary stents (7231 patients [58%] received drug-eluting stents) were implanted, and 1059 patients (8.5%) were treated with balloon angioplasty only. Baseline characteristics of the patients are shown in Table 1 . The proportion of women was 23.7% (2954 patients).
Bleeding Events
Bleeding events occurred in 374 patients (3.0%) according to the TIMI definition, 491 patients (3.9%) according to REPLACE-2 criteria, and 1233 patients (9.9%) according to BARC definition criteria (679 patients or 5.4% with BARC class Ն2 bleeding). The incidence of bleeding is shown in Table 2 .
Bleeding Events and Mortality
One-year follow-up was complete in all but 284 patients (2.3%). In patients with incomplete follow-up, the median follow-up (25th to 75th percentiles) was 6.5 (1.7-7.8) months. Overall, there were 54 deaths within the first 30 days after PCI (0.4%) and 340 deaths (2.7%) over the first year after PCI. One-year mortality differed slightly from 9.3% in patients with a BARC bleeding class Ն2 to 11.7% in patients with TIMI-defined major bleeding, demonstrating an increased risk of mortality across all 3 bleeding definition criteria, with a risk of dying of Ͼ4 times in patients with a BARC bleeding class Ն2 to a risk of dying of 5 times in those with TIMI-defined bleeding (major and minor) compared with patients who did not bleed ( Table 2) .
Landmark analysis demonstrated that the risk of dying in patients with bleeding continued to increase throughout the first year after the PCI procedure (Figures 1 and 2 ). The unadjusted hazard ratios related to bleeding from 30 days to 1 year after the PCI procedure are shown in Table 2 . There were slight differences in the bleeding-related risk of death across all bleeding definition criteria. Table 3 shows the 30-day and 1-year mortalities in various classes of BARC definition. As seen from Table 3 , there was a gradual increase in mortality at both 30 days and 1 year with increase in the severity of bleeding.
Predictors of Mortality
A univariable and multivariable Cox proportional hazards model was used to test the association of bleeding with 1-year mortality while adjusting for potential confounders. Univariable and multivariable predictors of 1-year mortality with baseline variables without bleeding are shown in Table II in the online-only Data Supplement. As stated in Methods, bleeding events were entered into the multivariable model on top of the baseline data (Table 1) . Overall, 5 multivariable models were constructed with baseline variables without bleeding and with bleeding as defined by BARC (dichotomized at BARC class Ն2 and BARC class Ն3), REPLACE-2, and TIMI criteria. The adjusted hazard ratios of 1-year mortality related to bleeding are shown in Table 4 . There was a marked increased risk of death conferred by bleeding, which is independent of all other clinical variables and baseline cardiovascular risk. In addition, the association between bleeding according to the 3 definitions and 1-year mortality was independent of the type of the study (P for interaction Ն0.624) or sex (P for interaction Ն0.223).
Comparison of Predictive Value of Bleeding Definitions
Sensitivity, specificity, and accuracy of bleeding events as defined by TIMI, REPLACE-2, or BARC with respect to 1-year mortality are calculated and shown in Table 5 . Overall, bleeding events as defined by TIMI, REPLACE-2, or BARC definitions were characterized by low sensitivity and high specificity and accuracy with respect to 1-year mortality.
BARC class Ն2 bleeding was more sensitive than BARC class Ն3, TIMI, or REPLACE-2 bleeding in regard to mortality prediction.
Predictivity of bleeding by TIMI, REPLACE-2, or BARC criteria in regard to 1-year mortality was assessed by calculating the adjusted AUC and IDI in multivariable models including each of the bleeding definitions. The AUC and the values of absolute and relative IDI of the models for 1-year mortality are shown in Table 6 . The inclusion of bleeding defined by all 3 definition criteria significantly improved the prediction of 1-year mortality. However, there were no significant differences in the predictivity of the models with BARC, TIMI, or REPLACE-2 bleeding in regard to 1-year Ն3 with the IDI of the models with TIMI or REPLACE-2 bleeding definitions). Adjusted receiver operating characteristic curves for 1-year mortality of the models without and with bleeding are shown in Figure 3 . Adjusted AUCs of all models are shown in Table 6 . It is notable that adjusted AUCs for all models including bleeding are significantly greater than adjusted AUCs for the model without bleeding (PՅ0.010); however, there were no significant differences in the adjusted AUC between the different models with bleeding according to BARC, TIMI, or REPLACE-2 criteria (PՆ0.170).
Discussion
The main findings of this study can be summarized as follows: (1) Bleeding events as defined by the BARC consensus document are independently associated with an increased risk of 1-year mortality across a wide spectrum of patients with coronary artery disease undergoing PCI. (2) There is a progressive increase in the risk of death at 1 year after PCI with increasing severity of bleeding as defined by the BARC hierarchical grading system. (3) The BARC definition of bleeding provides a predictive value in regard to 1-year mortality that is comparable to that provided by TIMI and REPLACE-2 bleeding definitions. Although the BARC bleeding definition appears to be more sensitive compared with bleeding events defined by TIMI or REPLACE-2 criteria in regard to 1-year mortality, this was achieved at the cost of a lower specificity.
A unified bleeding definition to be used in both everyday clinical routine and future studies is important for several reasons. Bleeding of various degrees occurs as often as ischemic complications in patients with acute coronary syndrome treated with antithrombotic treatment or patients undergoing PCI and is associated with substantial risk of mortality and morbidity, 1-7 longer hospital stay, 25 and increased economic costs. 26 An accurate and unified approach to assessment of bleeding events will help clinicians to stratify risks and to select an optimal treatment for their patients. A unified bleeding definition will be of particular importance for assessing new antithrombotic drugs as well as for testing bleeding avoidance strategies. Development and clinical use of potent platelet inhibitor drugs and a more widespread use of PCI in patients with acute coronary syndromes are expected to increase the frequency of bleeding complications at least for the foreseeable future. The existence of a multitude of bleeding definitions has led to inconsistencies and uncertainties in assessing and reporting bleeding events even in the same patient population. A study by Rao et al 27 has shown considerable differences in the reporting of bleeding events by applying TIMI and Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO) criteria in patients with non-ST-segment elevation acute coronary syndromes. Thus, the frequencies of minimal, minor, and major bleeding were 12.7%, 8.5%, and 8.2%, respectively, according to the TIMI definition, which contrasted with frequencies of 19.2%, 11.4%, and 1.2% of equivalent classes of mild, moderate, and severe bleeding according to GUSTO criteria. 27 In cases in which the same definition metric was used across various trials, differences in baseline bleeding risk, cointerventions, and outcome definitions hamper assessment of the true incidence of bleeding events. Variability in reported rates of major bleeding in trials of antithrombotic drugs depends heavily on the definition of major bleeding. A widely accepted unified bleeding definition is expected to overcome many of the aforementioned problems related to variability in bleeding definition and to enable an accurate assessment of bleeding events and successful implementation of bleeding avoidance strategies.
In the present study, we validated the newly proposed BARC bleeding definition criteria using a large number of patients with stable and unstable coronary artery disease undergoing PCI and antithrombotic therapy recruited in recently conducted randomized trials. We found that BARCdefined bleeding events were strongly associated with shortand long-term mortality up to 1 year after PCI procedures and that with regard to mortality prediction, BARC criteria offer prognostic information comparable to that provided by TIMI and REPLACE-2 bleeding definition criteria. The good performance of the BARC bleeding definition may be explained by several characteristics of the newly proposed definition. First, application of BARC criteria enables identification of a greater number of bleeding cases, especially of moderate to severe bleeding. Thus, the number of patients with bleeding requiring intervention (BARC class Ն2) or with severe bleeding (BARC class Ն3) was higher than the number classified as TIMI-defined minor plus major bleeding or REPLACE-2 major bleeding. The increased number of identified bleeding events could explain the better sensitivity of the newly proposed criteria in regard to mortality prediction. Second, the BARC proposed bleeding definition criteria offer a detailed hierarchical system of quantification of bleeding severity that is closely related to the increase in the risk of death. The increase in 1-year mortality from 2.7% in bleeding that does not require intervention (BARC class 1) to as high as 40% in severe bleeding (BARC class 3c) is a clear example of a close association between hierarchical grading of bleeding severity and risk of death. Third, the BARC definition offers a balanced combination of laboratory-based and clinically based metrics in bleeding definitions. Prior studies have emphasized the importance of the use of a balanced approach of laboratory-based and clinically oriented bleeding definition scales in assessment of the impact of bleeding on clinical outcome. 27 The most relevant limitation of the present study is the different timing of the adjudication of bleeding. More specifically, bleeding adjudication according to BARC criteria was done retrospectively. Therefore, data presented here need confirmation from studies based on prospectively adjudicated events. In the present study, the BARC bleeding definition was compared with the TIMI bleeding definition (major and minor) and the REPLACE-2 criteria. Although an array of other bleeding definitions exists, we chose these 2 bleeding definitions in particular as comparators because they were prospectively evaluated in source trials and because these bleeding definitions either were most commonly used (TIMI definition) or were specifically developed for interventional studies (REPLACE-2 definitions) such as those included in the present analysis. Another reason for selecting the REPLACE-2 bleeding definition as a comparator was that bleeding risk is higher in patients treated with an invasive approach compared with patients treated with a conservative medical approach across all categories of baseline bleeding risk. 28 In conclusion, the present validation study demonstrated a close association between bleeding events defined according to the newly proposed BARC bleeding definition criteria and 1-year mortality after PCI. The newly proposed BARC bleeding definition criteria offer a balanced combination of laboratory and clinical metrics for bleeding recognition and a detailed hierarchical grading system of severity that is closely associated with an increased risk of death up to 1 year after PCI. All 3 bleeding definitions (BARC, TIMI, and REPLACE-2) provide comparable prognostic information with respect to 1-year mortality in patients with coronary artery disease undergoing PCI.
Disclosures
None. /L, -known allergy to the study medication; -pregnancy (present or suspected); -reduced left ventricular function with an ejection fraction <30 percent.
In the ISAR-REACT-3 (19) and ISAR-REACT 3A (20) -trials exclusions included: -ST-segment elevation myocardial infarction within the last 48 hours, -troponin T > 0.03 μg/L or CK-MB > upper limit of the norm, -cardiogenic shock, -malignancy or other comorbid conditions (severe liver, renal, and pancreatic disease) with a life expectancy less than one year or that might be anticipated to require non-compliance with protocol, -active bleeding, bleeding diathesis, history of gastrointestinal or genitourinary bleeding within the last 6 weeks, -presence of diseases which have a high probability of vascular lesions and subsequent bleeding, such as active gastric ulcer or active ulcerous colitis trauma or major surgery in the last month, -ophthalmic or brain surgery in the last month, any history of intracranial bleeding or structural abnormalities, -aortic dissection, -pericarditis, -subacute bacterial endocarditis, -refusal to accept a blood transfusion, oral anticoagulation therapy within the last 7 days, -treatment with unfractionated heparin or low-molecular weight heparin in the previous 6 hours with an activated clotting time of 150 seconds or greater treatment with bivalirudin within 24 hours of randomization, -severe uncontrolled hypertension >180/110 mmHg unresponsive to therapy, -a planned staged percutaneous coronary intervention within 30 days or a percutaneous coronary intervention within the prior 30 days -hematologic abnormalities (hemoglobin <100 g/L, platelet count <100 x 109 /L) serum creatinine >30 mg/L or dependence on renal dialysis. Table I . Bleeding Defined by BARC, TIMI and REPLACE-2 Criteria BARC TIMI REPLACE-2 Type 0: no bleeding Type 1: bleeding that is not actionable and does not cause the patient to seek unscheduled performance of studies, hospitalization, or treatment by a healthcare professional; may include episodes leading to self-discontinuation of medical therapy by the patient without consulting a healthcare professional. Type 2: any overt, actionable sign of hemorrhage (eg, more bleeding than would be expected for a clinical circumstance, including bleeding found by imaging alone) that does not fit the criteria for type 3, 4, or 5 but does meet at least one of the following criteria: (1) requiring nonsurgical, medical intervention by a healthcare professional, (2) leading to hospitalization or increased level of care, or (3) prompting evaluation.
Type 3 Type 3a
Overt bleeding plus hemoglobin drop of 3 to <5 g/dL* (provided hemoglobin drop is related to bleed) Any transfusion with overt bleeding. Type 3b Overt bleeding plus hemoglobin drop ≥5 g/dL. * (provided hemoglobin drop is related to bleed). Cardiac tamponade. Bleeding requiring surgical intervention for control (excluding dental/nasal/skin/hemorrhoid). Bleeding requiring intravenous vasoactive agents. Type 3c Intracranial hemorrhage (does not include microbleeds or hemorrhagic transformation, does include intraspinal). Subcategories confirmed by autopsy or imaging or lumbar puncture. Intraocular bleed compromising vision. Type 4: CABG-related bleeding Perioperative intracranial bleeding within 48 h Reoperation after closure of sternotomy for the purpose of controlling bleeding.
TIMI major
Intracranial or clinically significant overt signs of hemorrhage associated with a greater than 50-g/L decrease in hemoglobin level or an absolute decrease in hematocrit of greater than 15% (when hemoglobin level was not available). The diagnosis of intracranial bleeding required confirmation by computed tomography or magnetic resonance imaging of the head.
TIMI minor
Observed blood loss and a decrease in hemoglobin level of 30 to 50 g/L (or, when hemoglobin level was not available, a decrease in the hematocrit of 9 to 15 percentage points) or a decrease in hemoglobin level of 40 g/L or greater (or ≥12% in hematocrit) if no bleeding site was identifiable. We also monitored for the REPLACE-2 major Intracranial, intraocular, or retroperitoneal hemorrhage; clinically overt blood loss resulting in a decrease in hemoglobin of more than 3 g per deciliter; any decrease in hemoglobin of more than 4 g per deciliter; or transfusion of 2 or more units of packed red cells or whole blood.
